Cellectis Reports Financial Results for First Quarter 2024

• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca

Related Keywords

United Kingdom ,North Carolina ,United States ,France ,Paris ,France General ,Raleigh ,New York ,Marc Dunoyer ,Patricia Sosa Navarro ,Arthur Stril ,Ashleyr Robinson ,Pascalyne Wilson ,Bing Wang ,Astrazeneca ,Research Plan ,Allogeneic Car Development Programs ,Group Share ,International Accounting Standards Board ,Nasdaq ,European Union ,Securities Exchange Commission ,International Financial Reporting Standards ,Cellectis The Company Euronext Growth ,Euronext Growth ,Chief Executive Officer ,Development Programs ,Investment Agreements ,Interim Chief Financial Officer ,Tyrell Rivers ,Subsequent Investment Agreement ,Net Income ,Regarding Use ,Nasdaq Global Market ,Private Securities Litigation Reform Act ,Annual Report ,Sosa Navarro ,Lifesci Advisors ,